Pub Date : 2022-01-01DOI: 10.14744/ejmo.2022.89238
Raja Benzeid
Objectives: Radio-resistance poses a major challenge in nasopharyngeal carcinoma (NPC) treatment. Due to individual variations in radio-sensitivity, biomarkers are needed to tailor radiation treatment. Within this frame, the identification of series of genetic signatures mainly SNPs for NPC patients treated with radiotherapy may help to predict treatment outcome and deliver personalized therapy. The aim of this study was to evaluate the possible association between the GSTP1 Ile105Val and GPX1 Pro198Leu polymorphisms and response to radiotherapy in NPC patients. Methods: From September 2016 to October 2018, a total of 101 patients with confirmed NPC, recruited at Mohammed IV Center for Treatment of Cancer of Casablanca, underwent radiotherapy. DNA was extracted from peripheral blood. Genotyping of the GPX1 Pro198Leu and GPX1 Val105Leu polymorphisms was carried out by PCR amplification and DNA sequencing. SPSS was used to analyse the association of GSTP1 and GPX1 genotypes with clinico-pathological features and response to radiotherapy. Results: The genotyping data revealed the presence of only two genotypes namely Pro/Pro (57.4%) and Pro/Leu (40.6%) for GPX1 gene. The allelic frequencies of C and T alleles were 78.7% and 21.3% respectively. For GSTP gene, the homozygous genotypes Val/Val and Leu/Leu were detected in 35.6% and 12.9% of patients respectively. The heterozygous genotype Val/Leu prevailed (51.5%). Allelic frequencies showed the presence of the two alleles A and G in 57.1% and 42.9% patients respectively. Statistical analysis failed to find any significant association between GSTP Val105Ile and GPX1 Pro198Leu genetic polymorphisms and socio-demographic and clinico-pathological features as well as response to radiotherapy (p>0.05). Conclusion: Further research is warranted on the potential role of SNPs within antioxidant defines genes in radiotherapy response and to identify reliable predictive and non-invasive biomarkers for radio-resistance among NPC patients for personalised therapies. Abstract Polymorphisms and Their Association with Response to Radiotherapy in Carcinoma
{"title":"GSTP1 Ile105Val and GPX1 Pro198Leu Polymorphisms and Their Association with Response to Radiotherapy in Nasopharyngeal Carcinoma Patients","authors":"Raja Benzeid","doi":"10.14744/ejmo.2022.89238","DOIUrl":"https://doi.org/10.14744/ejmo.2022.89238","url":null,"abstract":"Objectives: Radio-resistance poses a major challenge in nasopharyngeal carcinoma (NPC) treatment. Due to individual variations in radio-sensitivity, biomarkers are needed to tailor radiation treatment. Within this frame, the identification of series of genetic signatures mainly SNPs for NPC patients treated with radiotherapy may help to predict treatment outcome and deliver personalized therapy. The aim of this study was to evaluate the possible association between the GSTP1 Ile105Val and GPX1 Pro198Leu polymorphisms and response to radiotherapy in NPC patients. Methods: From September 2016 to October 2018, a total of 101 patients with confirmed NPC, recruited at Mohammed IV Center for Treatment of Cancer of Casablanca, underwent radiotherapy. DNA was extracted from peripheral blood. Genotyping of the GPX1 Pro198Leu and GPX1 Val105Leu polymorphisms was carried out by PCR amplification and DNA sequencing. SPSS was used to analyse the association of GSTP1 and GPX1 genotypes with clinico-pathological features and response to radiotherapy. Results: The genotyping data revealed the presence of only two genotypes namely Pro/Pro (57.4%) and Pro/Leu (40.6%) for GPX1 gene. The allelic frequencies of C and T alleles were 78.7% and 21.3% respectively. For GSTP gene, the homozygous genotypes Val/Val and Leu/Leu were detected in 35.6% and 12.9% of patients respectively. The heterozygous genotype Val/Leu prevailed (51.5%). Allelic frequencies showed the presence of the two alleles A and G in 57.1% and 42.9% patients respectively. Statistical analysis failed to find any significant association between GSTP Val105Ile and GPX1 Pro198Leu genetic polymorphisms and socio-demographic and clinico-pathological features as well as response to radiotherapy (p>0.05). Conclusion: Further research is warranted on the potential role of SNPs within antioxidant defines genes in radiotherapy response and to identify reliable predictive and non-invasive biomarkers for radio-resistance among NPC patients for personalised therapies. Abstract Polymorphisms and Their Association with Response to Radiotherapy in Carcinoma","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89578583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.14744/ejmo.2022.88799
pedro miguel dias dos Santos
Objectives: Colorectal cancer is the most frequent and mortal cancer in Portugal. Both angiogenesis and cellular proliferation are core mechanisms to tumoral progression, with VEGF (Vascular Endothelial Growth Factor) and Ki-67, respec-tively, being widely known markers of those two processes. The purposes of this study are to comprehend VEGF and Ki-67’s impact on colorectal cancer prognosis which include assessing its expression in primary colorectal cancer of patients who underwent surgery, establishing associations between the expression of VEGF and Ki-67 and discovering hypothetical associations between these biomarkers and clinicopathological aspects, relapse, and mortality of patients. Methods: A retrospective study was conducted in our hospital by including 512 patients submitted to surgery, from 2005 to 2010, with a post-operatory diagnosis of colorectal adenocarcinoma. The evaluation of expression of VEGF and Ki-67 in the obtained tissue was made through immunohistochemistry technique. The statistical analysis resourced to association tests and survival analysis. Results: VEGF-A showed association with the variable gender (p-value of 0.016), with its expression being more frequent in men. VEGF-C expression is more common in colon than in rectum (p- value of 0.042). VEGF-C is significantly associated with Ki-67 (p-value of 0.036), with 69.7% of cases where both are positive. All markers are significantly associated with the grade of differentiation, with the VEGF family generally more present in well or moderately differentiated tumours and Ki-67 in the poorly differentiated. While the survival time was generally lower in the presence of any marker or combination, no significant differences were found among the survival analysis. Conclusion: VEGF-A, VEGF-C and Ki-67 expression did not show impact on the prognosis of this sample of patients. There was no significant association with a poorer overall survival or a reduced disease-free survival.
{"title":"VEGF and Ki-67 Expression in Colorectal Cancer: The Long-Term Impact on Recurrence and Mortality","authors":"pedro miguel dias dos Santos","doi":"10.14744/ejmo.2022.88799","DOIUrl":"https://doi.org/10.14744/ejmo.2022.88799","url":null,"abstract":"Objectives: Colorectal cancer is the most frequent and mortal cancer in Portugal. Both angiogenesis and cellular proliferation are core mechanisms to tumoral progression, with VEGF (Vascular Endothelial Growth Factor) and Ki-67, respec-tively, being widely known markers of those two processes. The purposes of this study are to comprehend VEGF and Ki-67’s impact on colorectal cancer prognosis which include assessing its expression in primary colorectal cancer of patients who underwent surgery, establishing associations between the expression of VEGF and Ki-67 and discovering hypothetical associations between these biomarkers and clinicopathological aspects, relapse, and mortality of patients. Methods: A retrospective study was conducted in our hospital by including 512 patients submitted to surgery, from 2005 to 2010, with a post-operatory diagnosis of colorectal adenocarcinoma. The evaluation of expression of VEGF and Ki-67 in the obtained tissue was made through immunohistochemistry technique. The statistical analysis resourced to association tests and survival analysis. Results: VEGF-A showed association with the variable gender (p-value of 0.016), with its expression being more frequent in men. VEGF-C expression is more common in colon than in rectum (p- value of 0.042). VEGF-C is significantly associated with Ki-67 (p-value of 0.036), with 69.7% of cases where both are positive. All markers are significantly associated with the grade of differentiation, with the VEGF family generally more present in well or moderately differentiated tumours and Ki-67 in the poorly differentiated. While the survival time was generally lower in the presence of any marker or combination, no significant differences were found among the survival analysis. Conclusion: VEGF-A, VEGF-C and Ki-67 expression did not show impact on the prognosis of this sample of patients. There was no significant association with a poorer overall survival or a reduced disease-free survival.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"99 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86086218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.14744/ejmo.2022.11965
irene de la parra
Dear Editor, We have carefully read the response from Val-Bernal et al.,[1] and we feel sorry for any inconvenience that we may have caused. The purpose of our study[2] was to deepen the rare histologic type of renal tumor which is the chromophobe renal cancer with sarcomatoid differentiation, its mode of presentation, imaging techniques, histopathological analysis, prognostic factors, and treatment. Because it is a subject discussed in the literature but with only a few patients described, as a visual way to simplify the low incidence of this pathology, we used the results published by Bian et al.[3] on a table and added our clinical cases. With this, we reflected on the most important prognostic factors, as described in the literature, and how they affected survival. It is unquestionable that those two cases cited in Val-Bernal et al. could have enriched this table, especially because of their detailed histopathological analysis. Akhtar et al.[4] presented a left renal tumor with anaplastic spindle cells with a high mitotic rate intermingled with poorly differentiated pleomorphic tumor cells showing positivity for vimentin. In the same way, Gómez-Román et al.[5] showed a right renal mass with sheets of voluminous polygonal epithelial cells with 40% of the tumor displaying spindle-shaped and pleomorphic cells, showing epithelial cell diffuse reaction of the cytoplasm with Hale’s acid iron colloid stain and being the sarcomatoid areas reacted for vimentin. It should also be noted, as they argue in their letter, that their patient was alive 7 years after diagnosis, which is the longest survival time described in this type of patients. Nevertheless, as far as our review is concerned, we decided to focus more on the literature described in terms of prognostic factors and optimal treatment based on these than on the exact number of cases described, and that is the reason why unfortunately we did not add the case presented in 1996, which might have surely completed our series both in quantitative and qualitative terms. Please accept our apologies for any discomfort, and we hope that this will not happen again in the future as our ultimate goal is to combine the maximum knowledge with the previously described pertinent literature to manage complex patients in the best possible way. Irene De La Parra,1 Álvaro Serrano,1 Roser Vives,1 Juan Hermida,1 Luis Ignacio Diez-Valladares,2 Jerónimo Barrera,3 José Antonio Cortés,4 Pilar González-Peramato,5 Ángel Gómez,1 Jesús Moreno1
尊敬的编辑:我们已经仔细阅读了Val-Bernal等人的回复[1]，对于由此造成的不便，我们深表歉意。我们的研究[2]的目的是深入了解罕见的肾肿瘤的组织学类型，即具有肉瘤样分化的嫌色肾癌，其表现方式，影像学技术，组织病理学分析，预后因素和治疗。由于这是一个文献讨论的主题，但只有少数患者被描述，为了直观地简化这种病理的低发病率，我们在表格上使用了Bian等人[3]发表的结果，并添加了我们的临床病例。由此，我们反思了文献中描述的最重要的预后因素，以及它们如何影响生存。毫无疑问，Val-Bernal等人引用的那两个病例可以丰富这个表格，特别是因为他们详细的组织病理学分析。Akhtar等[4]报道了一个左肾肿瘤，有丝分裂率高的间变性梭形细胞混杂着低分化多形性肿瘤细胞，显示波形蛋白阳性。同样，Gómez-Román等人[5]显示右侧肾肿块，有大量的多角形上皮细胞，40%的肿瘤呈梭形和多形性细胞，显示上皮细胞在Hale酸铁胶体染色下细胞质弥漫性反应，为类肉瘤区对波形蛋白反应。还应该指出的是，正如他们在信中所说，他们的病人在诊断后还活着7年，这是这类病人中最长的生存时间。然而，就我们的回顾而言，我们决定更多地关注预后因素和基于这些因素的最佳治疗方法的文献，而不是所描述的病例的确切数量，这就是为什么不幸的是，我们没有增加1996年提出的病例，这肯定会在定量和定性方面完成我们的系列。对于给您带来的任何不适，请接受我们的歉意，我们希望这种情况不会再次发生，因为我们的最终目标是将最大限度的知识与先前描述的相关文献相结合，以最好的方式管理复杂的患者。Irene De La Parra,1 Álvaro Serrano,1 Roser Vives,1 Juan Hermida,1 Luis Ignacio Diez-Valladares,2 Jerónimo Barrera,3 jossore,4 Pilar González-Peramato,5 Ángel Gómez,1 Jesús Moreno1
{"title":"Sarcomatoid Transformation of Chromophobe Renal Cell Carcinoma: An unusual Pathology","authors":"irene de la parra","doi":"10.14744/ejmo.2022.11965","DOIUrl":"https://doi.org/10.14744/ejmo.2022.11965","url":null,"abstract":"Dear Editor, We have carefully read the response from Val-Bernal et al.,[1] and we feel sorry for any inconvenience that we may have caused. The purpose of our study[2] was to deepen the rare histologic type of renal tumor which is the chromophobe renal cancer with sarcomatoid differentiation, its mode of presentation, imaging techniques, histopathological analysis, prognostic factors, and treatment. Because it is a subject discussed in the literature but with only a few patients described, as a visual way to simplify the low incidence of this pathology, we used the results published by Bian et al.[3] on a table and added our clinical cases. With this, we reflected on the most important prognostic factors, as described in the literature, and how they affected survival. It is unquestionable that those two cases cited in Val-Bernal et al. could have enriched this table, especially because of their detailed histopathological analysis. Akhtar et al.[4] presented a left renal tumor with anaplastic spindle cells with a high mitotic rate intermingled with poorly differentiated pleomorphic tumor cells showing positivity for vimentin. In the same way, Gómez-Román et al.[5] showed a right renal mass with sheets of voluminous polygonal epithelial cells with 40% of the tumor displaying spindle-shaped and pleomorphic cells, showing epithelial cell diffuse reaction of the cytoplasm with Hale’s acid iron colloid stain and being the sarcomatoid areas reacted for vimentin. It should also be noted, as they argue in their letter, that their patient was alive 7 years after diagnosis, which is the longest survival time described in this type of patients. Nevertheless, as far as our review is concerned, we decided to focus more on the literature described in terms of prognostic factors and optimal treatment based on these than on the exact number of cases described, and that is the reason why unfortunately we did not add the case presented in 1996, which might have surely completed our series both in quantitative and qualitative terms. Please accept our apologies for any discomfort, and we hope that this will not happen again in the future as our ultimate goal is to combine the maximum knowledge with the previously described pertinent literature to manage complex patients in the best possible way. Irene De La Parra,1 Álvaro Serrano,1 Roser Vives,1 Juan Hermida,1 Luis Ignacio Diez-Valladares,2 Jerónimo Barrera,3 José Antonio Cortés,4 Pilar González-Peramato,5 Ángel Gómez,1 Jesús Moreno1","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"57 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86777891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.14744/ejmo.2021.85983
V. Abbate
Objectives: Preoperative diagnostic investigation of salivary neoplasms leaves a fair share of doubtful cases that complicate the therapeutic choices. The aim of our study was to look for new means to support the decision-making process for their management. Inflammatory biomarkers could play an important role in this process. Methods: A retrospective chart review of salivary glands tumors was performed between January 2016 and September 2020 in our Department. The samples were divided in 2 groups basing on the histological result after surgery: 191 patients with benign salivary glands tumors (SGbt), and 47 with salivary glands cancer (SGc). 90 patients were randomly selected to form the control group (C group). Results: Statistically significant increase of platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocite ratio (NLR) and systemic immune-inflammation index (SII) was reported in SGc group compared to SGbt group and control group (p<0.001). Statistical evaluation estabilished optimal threshold for PLR (164,2), NLR (3,11) and SII (517.5) that can discriminate the doubtful cases with specificity of 85-86% and 62% respectively, and sensitivity of 40-45% and 64% respectively. Conclusion: Inflammatory biomarkers can have a relevant role as diagnostic tools in doubtful cases. They could be performed in the clinical setting for guiding the treatment of these neoplasms.
{"title":"Relevance of Inflammatory Biomarkers in Salivary Gland Cancers Management","authors":"V. Abbate","doi":"10.14744/ejmo.2021.85983","DOIUrl":"https://doi.org/10.14744/ejmo.2021.85983","url":null,"abstract":"Objectives: Preoperative diagnostic investigation of salivary neoplasms leaves a fair share of doubtful cases that complicate the therapeutic choices. The aim of our study was to look for new means to support the decision-making process for their management. Inflammatory biomarkers could play an important role in this process. Methods: A retrospective chart review of salivary glands tumors was performed between January 2016 and September 2020 in our Department. The samples were divided in 2 groups basing on the histological result after surgery: 191 patients with benign salivary glands tumors (SGbt), and 47 with salivary glands cancer (SGc). 90 patients were randomly selected to form the control group (C group). Results: Statistically significant increase of platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocite ratio (NLR) and systemic immune-inflammation index (SII) was reported in SGc group compared to SGbt group and control group (p<0.001). Statistical evaluation estabilished optimal threshold for PLR (164,2), NLR (3,11) and SII (517.5) that can discriminate the doubtful cases with specificity of 85-86% and 62% respectively, and sensitivity of 40-45% and 64% respectively. Conclusion: Inflammatory biomarkers can have a relevant role as diagnostic tools in doubtful cases. They could be performed in the clinical setting for guiding the treatment of these neoplasms.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"74 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87997562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Utility of EORTC and CUETO Scoring Models in the Estimation of Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer","authors":"M. El Mzibri","doi":"10.14744/ejmo.2022.99203","DOIUrl":"https://doi.org/10.14744/ejmo.2022.99203","url":null,"abstract":"DOI: 10.14744/ejmo.2022.99203 EJMO 2022;6(2):121–129","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"62 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78665869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.14744/ejmo.2022.19570
M. Zouari
Objectives: Necrotizing enterocolitis (NEC) is a severe neonatal condition. This study aimed to assess predictive factors for surgical treatment in preterm neonates with NEC in a Tunisian center. Methods: We present a retrospective study including all neonates treated for NEC between January 01, 2010 and March 31, 2022. Results: Within the study period, 102 patients were included, with an overall survival of 47%. Most of our patients were male (64.7%), with low birth weight or less (100%), 5-min Apgar score ≥8 (79.4%), and Bell’s stage II (66.7%). Multivariate logistic analyses demonstrated that gestational age <30 weeks (p=0.002, odds ratio [OR]=4.544), birth weight <1000 g (p=0.001, OR=5.750), NEC onset <7 days (p<0.001, OR=5.667), not being breastfed (p=0.019, OR=3.026), and C-reactive protein level >20 mg/L (p=0.020, OR=2.942) were associated with the need for surgical treatment in neonates with NEC. Conclusion: Our findings would be helpful in refining treatment modalities for better disease outcomes.
{"title":"Predictive Factors for Surgery in Preterm Neonates with Necrotizing Enterocolitis: A Retrospective Cohort Study","authors":"M. Zouari","doi":"10.14744/ejmo.2022.19570","DOIUrl":"https://doi.org/10.14744/ejmo.2022.19570","url":null,"abstract":"Objectives: Necrotizing enterocolitis (NEC) is a severe neonatal condition. This study aimed to assess predictive factors for surgical treatment in preterm neonates with NEC in a Tunisian center. Methods: We present a retrospective study including all neonates treated for NEC between January 01, 2010 and March 31, 2022. Results: Within the study period, 102 patients were included, with an overall survival of 47%. Most of our patients were male (64.7%), with low birth weight or less (100%), 5-min Apgar score ≥8 (79.4%), and Bell’s stage II (66.7%). Multivariate logistic analyses demonstrated that gestational age <30 weeks (p=0.002, odds ratio [OR]=4.544), birth weight <1000 g (p=0.001, OR=5.750), NEC onset <7 days (p<0.001, OR=5.667), not being breastfed (p=0.019, OR=3.026), and C-reactive protein level >20 mg/L (p=0.020, OR=2.942) were associated with the need for surgical treatment in neonates with NEC. Conclusion: Our findings would be helpful in refining treatment modalities for better disease outcomes.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78886975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.14744/ejmo.2023.96531
M. Botlagunta
Objectives: To discover micro ribonucleic acids (miRNAs) involved in the regulation of DDX3 expression using sexual hormones in combination with the well-known anticancer medication cisplatin. Methods: SiHa cells were treated with estradiol, dihydrotestosterone, and cisplatin and evaluated the expression of ER beta, Ki67, and DDX3 via quantitative reverse transcription–polymerase chain reaction. We generated a chimeric fusion construct five untranslated region (UTR)–hLUC–3UTR in the pEZX-MT06 miRNA vector under the control of the SV40 promoter. Reporter activity is measured with/without hormones, and their activity is compared with 5'- and 3'-UTR respectively. Various reporter deletion constructs were generated to identify the minimal UTR region in regulating the expression of DDX3. We identified the potential miRNA binding sites on the DDX3 UTR region, and their expression is monitored in cancer patients and cisplatin-treated SiHa cells. Results: Hormones increased the proliferation of SiHa cells and expression of DDX3. The 3'-UTR region 2135–4307bp contains miRNA sites that regulate DDX3 expression. miRNAs hsa-miR-671-5p, hsa-miR-361-5p, hsa-miR-140-5p, hsa-miR-564, and hsa-miR-769-5p downregulated in patient samples but upregulated in cisplatin-treated cells. miRNA hsa-miR-671-5p and hsa-miR-564 were associated with patient data and cisplatin-treated cancer cells. Conclusion: We discovered that sexual hormones enhanced DDX3 expression in SiHa cells. MiR-671-5p and miR-564 are two potential therapeutic miRNAs that can be used to treat DDX3-related malignancies.
{"title":"Differential Expression of DDX3 and microRNAs in Response to Hormone and Cisplatin Against Cervical Cancer","authors":"M. Botlagunta","doi":"10.14744/ejmo.2023.96531","DOIUrl":"https://doi.org/10.14744/ejmo.2023.96531","url":null,"abstract":"Objectives: To discover micro ribonucleic acids (miRNAs) involved in the regulation of DDX3 expression using sexual hormones in combination with the well-known anticancer medication cisplatin. Methods: SiHa cells were treated with estradiol, dihydrotestosterone, and cisplatin and evaluated the expression of ER beta, Ki67, and DDX3 via quantitative reverse transcription–polymerase chain reaction. We generated a chimeric fusion construct five untranslated region (UTR)–hLUC–3UTR in the pEZX-MT06 miRNA vector under the control of the SV40 promoter. Reporter activity is measured with/without hormones, and their activity is compared with 5'- and 3'-UTR respectively. Various reporter deletion constructs were generated to identify the minimal UTR region in regulating the expression of DDX3. We identified the potential miRNA binding sites on the DDX3 UTR region, and their expression is monitored in cancer patients and cisplatin-treated SiHa cells. Results: Hormones increased the proliferation of SiHa cells and expression of DDX3. The 3'-UTR region 2135–4307bp contains miRNA sites that regulate DDX3 expression. miRNAs hsa-miR-671-5p, hsa-miR-361-5p, hsa-miR-140-5p, hsa-miR-564, and hsa-miR-769-5p downregulated in patient samples but upregulated in cisplatin-treated cells. miRNA hsa-miR-671-5p and hsa-miR-564 were associated with patient data and cisplatin-treated cancer cells. Conclusion: We discovered that sexual hormones enhanced DDX3 expression in SiHa cells. MiR-671-5p and miR-564 are two potential therapeutic miRNAs that can be used to treat DDX3-related malignancies.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73152710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prognostic Importance of DUSP22 (Dual Specificity Phosphatase 22) Gene Expression in Low-Grade Lymphomas","authors":"S. Paydaş","doi":"10.14744/ejmo.2021.59080","DOIUrl":"https://doi.org/10.14744/ejmo.2021.59080","url":null,"abstract":"DOI: 10.14744/ejmo.2021.59080 EJMO 2021;5(4):327–331","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85312548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.14744/ejmo.2022.38937
S. Lee
Human papillomaviruses (HPV) are one of the first viral organisms acknowledged to causing carcinogenesis. Among gynecologic cancers, Pap smear represents a gold standard diagnostic procedure for precancerous cervical lesions. It is efficiently interpreted through a standardized reporting system; The Bethesda System, which aids in distinguishing squamous categories from other entities. Co-infections with other sexually transmitted infections (STIs) could exacerbate cervical lesion severity caused by initial HPV infection as co-infections can lead to distinct reprogramming of host cells and genome integrity. The intricate pathways and effect of the unique cellular microenvironment that HPV and co-infecting STIs create that cause local inflammation and eventually cervical lesion progression will be reviewed in this manuscript. Besides, it is also crucial to consider HPV viral load and distinguish its correlation with cervical lesion severity. Varying amounts of viral titer and its impact on cervical lesions could indicate a mutagenic transformation of the human host cells and HPV. Thus, this review aims to discuss the correlation of co-infections and viral titer on cervical lesion severity and its progression to cancer. Based on these factors, clear clinical reasoning with more effective treatment plans and specific diagnostics can be achieved.
{"title":"Association of High-risk Human Papillomavirus Titer and Pathogenic Co-infections with Cervical Tissue Cytopathology","authors":"S. Lee","doi":"10.14744/ejmo.2022.38937","DOIUrl":"https://doi.org/10.14744/ejmo.2022.38937","url":null,"abstract":"Human papillomaviruses (HPV) are one of the first viral organisms acknowledged to causing carcinogenesis. Among gynecologic cancers, Pap smear represents a gold standard diagnostic procedure for precancerous cervical lesions. It is efficiently interpreted through a standardized reporting system; The Bethesda System, which aids in distinguishing squamous categories from other entities. Co-infections with other sexually transmitted infections (STIs) could exacerbate cervical lesion severity caused by initial HPV infection as co-infections can lead to distinct reprogramming of host cells and genome integrity. The intricate pathways and effect of the unique cellular microenvironment that HPV and co-infecting STIs create that cause local inflammation and eventually cervical lesion progression will be reviewed in this manuscript. Besides, it is also crucial to consider HPV viral load and distinguish its correlation with cervical lesion severity. Varying amounts of viral titer and its impact on cervical lesions could indicate a mutagenic transformation of the human host cells and HPV. Thus, this review aims to discuss the correlation of co-infections and viral titer on cervical lesion severity and its progression to cancer. Based on these factors, clear clinical reasoning with more effective treatment plans and specific diagnostics can be achieved.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84688463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：